CGP53353 is a selective inhibitor of PKCβII (IC50 are 0.41 and 3.8 μM for PKCβII and PKCβI respectively). CGP53353 also inhibits prionogenic Sup35 fibrillization (IC50 ~ 3.4 μM) and inhibits de novo Aβ42 assembly in vitro. References: Liu Y, Jin J, Qiao S, Lei S, Liao S, Ge ZD, Li H, Wong GT, Irwin MG, Xia Z. Inhibition of PKCβ2 overexpression ameliorates myocardial ischaemia/reperfusion injury in diabetic rats via restoring caveolin-3/Akt signaling. Clin Sci (Lond). 2015 Aug;129(4):331-44. doi: 10.1042/CS20140789. PubMed PMID: 25849791.

纯度：≥98%

CAS：145915-60-2